IAP20Rec'd PCT/PTO 11 MAY 2006

Practitioner's Docket No. 700953-53676

IN THE UNITED STATES RECEIVING OFFICE

International Application Number	International Filing Date	International Earliest Priority Date	
PCT/US2004/038643	12 November 2004 (12.11.2004)	12 November 2003 (12.11.2003)	

TITLE OF INVENTION:

CUSTOM VECTORS FOR TREATING AND

PREVENTING PANCREATIC CANCER

APPLICANT FOR DO/US/RO: THERION BIOLOGICS CORPORATION, et al.

CE	RTIFICATE OF MAILING
I hereby certify that this corre	espondence, on the date shown below, is being
deposited with the United Sta	ates Postal Service with sufficient postage as Express
Mail Label No. EV 65300323	74 US in an envelope addressed to MAIL STOP PCT,
Commissioner for Patents, P. Date: May 11, 2006	O. Box 1450, Mexandria, VA 2/313-1/50. Signature Linda M: Ginsberg

MAIL STOP PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir/Madam:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §1.56, 1.97, and 1.98, Applicants wish to bring to the Examiner's attention the following references, References B1 and C1-C4 cited in the attached Forms PTO/SB/08a and b.

REMARKS

	In accordance with the provisions of 37 C.F.R. §1.97, this statement is being				
filed:					
<u>X</u>	(1)	within three (3) months of the Filing Date or before the mailing date of the First Office Action on the merits; or			
	(2)	within three months of the mailing date of the PCT International			

10/579025

IN THE UNITED STATES RECEIVING OFFICE TO 11 MAY 2000 International Earliest Priority Date **International Filing Date International Application** Number 12 November 2004 12 November 2003 PCT/US2004/038643 (12.11.2003) (12.11.2004)

TITLE OF INVENTION:		CUSTOM VECTORS FOR TREATING AND PREVENTING PANCREATIC CANCER		
APPLICANT FOR	DO/US/R			
	(3)	after the period defined in (1) but before the mailing date of a Final Rejection or Notice of Allowance, and the requisite Certification or fee under Rule 1.17(p), namely \$180.00, is included herein; or		
	(4)	after the mailing date of a Final Rejection or Notice of Allowance but before the payment of the Issue Fee, and the requisite Certification, petition, and petition fee are included herein.		
_X	А сору	of the International Search Report is enclosed herewith.		
		pectfully requested that each of the documents shown on the attached PTO/SB/08a and b be made of record in this application.		
	Copies	of these documents (CHECK ONE):		
_X	are enclosed herewith; or			
	have been cited in the parent application, and are thus not being resubmitted herein.			
X	Pursuant to 37 C.F.R. §1.98, copies of issued U.S. patents listed on the attached form PTO/SB/08, if any, are no longer required and therefore are no enclosed. These documents can be found in the U.S. PTO issued patents database.			

FEE AUTHORIZATION

The Commissioner is authorized to charge fee deficiencies or credit overpayments associated with this submission to the NIXON PEABODY LLP Deposit Account No. 50-0850.

Date: May 11, 2006

Respectfully submitted,

Ronald I. Eisenstein (Reg. No. 30,628)

Leena H. Karttunen (L0207)

NIXON PEABODY LLP

100 Summer Street

Boston, MA 02110-2131

(617) 345-6054

JAP20Rec'd PCT/PTO 11 MAY 2006

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	 of	2

Complete if Known 570025					
Application Number	To be assigned 579025				
I.A. Filing Date	12 November 2004				
First Named Inventor	Dennis L. Panicali				
Art Unit	To be assigned				
Examiner Name	To be assigned				
Attorney Docket Number	700953-53676				

		-	U.S. PATENT DO	CUMENTS		
Examiner Initials	Cite No.	U.S. Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
		Number - Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	
		110 6 527 552	02.272002	MINION et el		
		US-6,537,552	03-272003	MINION et al.		
		US-5,827,666	10-27-1998	FINN et al.		
		US-				
		US-				
		US-				
		US-				
, <u> </u>		US-				
		US-				
		US-				
• • • • • • • • • • • • • • • • • • • •		US-				
		US-				
· · · · · · · · · · · · · · · · · · ·		US-				
		US-				
_		US-				
		US-				
		US-				
		US-	<u> </u>			
		US-				
		US-				

		FC	REIGN PATENT I	DOCUMENTS		
Examiner Cite Initials No.1		Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
		Country Code ³ Number ⁴ (if known)	MM-DD-YYYY		Figures Appear	T4
	B1	WO 98/04727	02-05-1998	Therion Biologics Corp. et al.		
				•		
· · · · · · · · · · · · · · · · · · ·						
				}		

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

			APAII!	or a length of 1	1 nany 2006	
Substitute	e for form 1449A/PTO			किंदिए कि एक विस्तृ में.	Complete if Known	
INFO	DMATION	DISC	AGURE	Application Number	To be assigned	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				I.A. Filing Date	1 Nonber 20件 2	
SIAI				First Named Inventor	Dennis L. Panicali	
	(use as many sheets o	as necesso	(צמו	Art Unit	To be assigned	
		\		Examiner Name	To be assigned	
Sheet	2	of	2	Attorney Docket Number	700953-53676	

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
	C1	AARTS, Wilhelmina M. et al.; Cancer Research; 62:5770-5777 (October 15, 2002)					
	C2	SCHLOM, Jeffrey et al.; Breast Cancer Research and Treatment; 38:27-39 (1996)					
	C3	SCHOLL, Susy et al.; Journal of Biomedicine and Biotechnology; 3:194-201 (2003)					
	C4	ZAJAC, P. et al.; Human Gene Therapy; 14:1497-1510 (November 1, 2003)					
	C5	GROSENBACH et al., Cancer Research, June 2001, vol. 61, 4497-4050					
· · · · · · · · · · · · · · · · · · ·	C6	GREINER et al., Cancer Research, December 2002, vol. 62, 6944-6951					
<u> </u>							

Exa	miner	•	Date
Sign	nature		Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.